Literature DB >> 6133212

Effect of somatostatin on vasopressin-induced antidiuresis and renal cyclic AMP of rats.

S N Winkler, S Torikai, B S Levine, K Kurokawa.   

Abstract

Effects of somatostatin (SRIF) on vasopressin-stimulated antidiuresis and on cyclic AMP in renal medulla in vivo and in microdissected tubule segments were examined in rats. An intravenous infusion of SRIF abolished vasopressin-induced antidiuresis without significant changes in urinary solutes and creatinine excretion in water diuresing rats: urinary osmolality rose from 131 +/- 12 to 587 +/- 20 mOsm/kg H2O in rats receiving vasopressin while urinary osmolality rose from 103 +/- 7 to only 258 +/- 25 mOsm/kg H2O in response to vasopressin with SRIF. This effect of SRIF was reversible. SRIF diminished only slightly the vasopressin-stimulated increases in cyclic AMP in renal medulla in vivo. In both cortical and medullary collecting tubules as well as in the medullary thick ascending limb of Henle's loop microdissected from rat kidney, SRIF partially inhibited vasopressin-dependent increases in cell cyclic AMP concentrations. These data demonstrate an inhibition by SRIF of vasopressin-stimulated anti-diuresis in rats and suggest that the mechanisms involved may be, at least partly, an inhibition of cyclic AMP formation in response to vasopressin in the collecting tubules.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6133212

Source DB:  PubMed          Journal:  Miner Electrolyte Metab        ISSN: 0378-0392


  11 in total

1.  Randomized clinical trial of long-acting somatostatin for autosomal dominant polycystic kidney and liver disease.

Authors:  Marie C Hogan; Tetyana V Masyuk; Linda J Page; Vickie J Kubly; Eric J Bergstralh; Xujian Li; Bohyun Kim; Bernard F King; James Glockner; David R Holmes; Sandro Rossetti; Peter C Harris; Nicholas F LaRusso; Vicente E Torres
Journal:  J Am Soc Nephrol       Date:  2010-04-29       Impact factor: 10.121

2.  Novel treatments of autosomal dominant polycystic kidney disease.

Authors:  Rex L Mahnensmith
Journal:  Clin J Am Soc Nephrol       Date:  2014-04-10       Impact factor: 8.237

Review 3.  Strategies targeting cAMP signaling in the treatment of polycystic kidney disease.

Authors:  Vicente E Torres; Peter C Harris
Journal:  J Am Soc Nephrol       Date:  2013-12-12       Impact factor: 10.121

Review 4.  Novel therapeutic approaches to autosomal dominant polycystic kidney disease.

Authors:  Wells B LaRiviere; Maria V Irazabal; Vicente E Torres
Journal:  Transl Res       Date:  2014-11-13       Impact factor: 7.012

5.  Safety study of somatostatin analogue octreotide for autosomal dominant polycystic kidney disease in Japan.

Authors:  Eiji Higashihara; Kikuo Nutahara; Takatsugu Okegawa; Mitsuhiro Tanbo; Hideaki Mori; Isao Miyazaki; Toshiaki Nitatori; Kuninori Kobayashi
Journal:  Clin Exp Nephrol       Date:  2014-10-29       Impact factor: 2.801

Review 6.  Rare cystic liver lesions: a diagnostic and managing challenge.

Authors:  Andreas Bakoyiannis; Spiros Delis; Charina Triantopoulou; Christos Dervenis
Journal:  World J Gastroenterol       Date:  2013-11-21       Impact factor: 5.742

Review 7.  Heterotrimeric G protein signaling in polycystic kidney disease.

Authors:  Taketsugu Hama; Frank Park
Journal:  Physiol Genomics       Date:  2016-05-13       Impact factor: 3.107

Review 8.  Modulation of polycystic kidney disease by G-protein coupled receptors and cyclic AMP signaling.

Authors:  Caroline R Sussman; Xiaofang Wang; Fouad T Chebib; Vicente E Torres
Journal:  Cell Signal       Date:  2020-04-23       Impact factor: 4.315

9.  Somatostatin in renal physiology and autosomal dominant polycystic kidney disease.

Authors:  A Lianne Messchendorp; Niek F Casteleijn; Esther Meijer; Ron T Gansevoort
Journal:  Nephrol Dial Transplant       Date:  2020-08-01       Impact factor: 5.992

10.  c-JUN n-Terminal Kinase (JNK) Signaling in Autosomal Dominant Polycystic Kidney Disease.

Authors:  Abigail O Smith; Julie A Jonassen; Kenley M Preval; Roger J Davis; Gregory J Pazour
Journal:  J Cell Signal       Date:  2022
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.